Vor Biopharma (NASDAQ:VOR) Shares Down 5.1% – Time to Sell?

Vor Biopharma Inc. (NASDAQ:VOR) fell 5.1% on Monday . The company traded as low as $19.79 and last traded at $19.5450. 179,481 shares were traded during trading, a decline of 83% from the average daily volume of 1,076,841 shares. The stock had previously closed at $20.59.

Wall Street Analyst Weigh In

Several analysts have issued reports on VOR shares. Wells Fargo & Company initiated coverage on Vor Biopharma in a research note on Thursday, March 19th. They issued an “overweight” rating and a $30.00 target price for the company. Jefferies Financial Group raised shares of Vor Biopharma to a “strong-buy” rating in a research note on Thursday, April 30th. Wedbush upped their price objective on shares of Vor Biopharma from $15.00 to $18.00 and gave the company a “neutral” rating in a research note on Thursday, May 14th. Weiss Ratings raised shares of Vor Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, June 30th. Finally, HC Wainwright reiterated a “buy” rating and issued a $31.00 target price on shares of Vor Biopharma in a research report on Monday, May 18th. Two analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $42.25.

Vor Biopharma Stock Performance

The firm has a 50-day moving average of $15.38 and a 200-day moving average of $14.74.

Vor Biopharma (NASDAQ:VOR) last released its quarterly earnings data on Monday, March 30th. The company reported $307.61 earnings per share for the quarter. On average, analysts predict that Vor Biopharma Inc. will post -2.51 earnings per share for the current year.

Insiders Place Their Bets

In other Vor Biopharma news, Director Ra Capital Management, L.P. sold 165,150 shares of the stock in a transaction on Wednesday, April 22nd. The shares were sold at an average price of $15.77, for a total transaction of $2,604,415.50. Following the completion of the sale, the director owned 2,402,095 shares of the company’s stock, valued at $37,881,038.15. This represents a 6.43% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Over the last three months, insiders have sold 1,669,542 shares of company stock worth $26,918,569. Corporate insiders own 0.27% of the company’s stock.

Hedge Funds Weigh In On Vor Biopharma

Hedge funds and other institutional investors have recently modified their holdings of the company. China Universal Asset Management Co. Ltd. bought a new stake in shares of Vor Biopharma in the fourth quarter worth about $36,000. Goldman Sachs Group Inc. raised its position in Vor Biopharma by 218.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock valued at $61,000 after purchasing an additional 58,247 shares during the last quarter. XTX Topco Ltd purchased a new stake in Vor Biopharma in the 2nd quarter worth approximately $66,000. Chung Wu Investment Group LLC purchased a new stake in Vor Biopharma in the 4th quarter worth approximately $109,000. Finally, Susquehanna Portfolio Strategies LLC bought a new stake in shares of Vor Biopharma in the 4th quarter worth approximately $134,000. 97.29% of the stock is owned by institutional investors.

About Vor Biopharma

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).